Status:
COMPLETED
Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Acute Kidney Injury
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Acute kidney injury (AKI) occurs in up to 30% of patients undergoing coronary artery bypass graft (CABG) surgery, and often requires patients to go on dialysis. In patients needing dialysis, the risk ...
Detailed Description
This is a randomized double-blinded study investigating the role of DigiFab in patients with elevated risk of acute kidney injury undergoing CABG surgery. University of Maryland Medical Center (UMMC) ...
Eligibility Criteria
Inclusion
- Undergoing coronary artery bypass surgery
- glomerular filtration rate \> 15 History of Diabetes Mellitus or GFR \< 60
Exclusion
- Allergy to Digifab Contrast dye within 3 days Creatinine \> 25% above baseline
Key Trial Info
Start Date :
July 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2024
Estimated Enrollment :
267 Patients enrolled
Trial Details
Trial ID
NCT03810417
Start Date
July 22 2019
End Date
April 30 2024
Last Update
July 2 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland
Baltimore, Maryland, United States, 21201
2
St Josephs Medical Center
Baltimore, Maryland, United States, 21204